PIK3CA and lung cancer: In order to test the hypothesis that a PIK3CA-activating mutation drives resistance to osimertinib, we introduced the PIK3CA H1047R (hereafter referred to as PIK3CAm) variant in three lung cancer cell line models using a CRISPR/Cas9 technology: PC9, PC9-T790M and HCC827.